• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Magnetosomes as Potential Nanocarriers for Cancer Treatment
Curr Drug Deliv. 2023 Jun 19. doi: 10.2174/1567201820666230619155528. Online ahead of print.ABSTRACTMagnetotactic bacteria (MTBs) and their organelles, magnetosomes, are intriguing options that might fulfill the criteria of using bacterial magnetosomes (BMs). The ferromagnetic crystals contained in BMs can condition the magnetotaxis of MTBs, which is common in water storage facilities. This review provides an overview of the feasibility of using MTBs and BMs as nanocarriers in cancer treatment. More evidence suggests that MTBs and BMs can be used as natural nanocarriers for conventional anticancer medicines, antibodies, va...
Source: Current Drug Delivery - June 21, 2023 Category: Drugs & Pharmacology Authors: Rawan Alsharedeh Nid'a Alshraiedeh Alaa A Aljabali Murtaza M Tambuwala Source Type: research

Retraction Note: Combination Cancer Immunotherapy with Dendritic Cell Vaccine and Nanoparticles Loaded with Interleukin-15 and Anti-beta-catenin siRNA Significantly Inhibits Cancer Growth and Induces Anti-Tumor Immune Response
Source: Pharmaceutical Research - December 7, 2022 Category: Drugs & Pharmacology Source Type: research

Directing the Way —Receptor and Chemical Targeting Strategies for Nucleic Acid Delivery
AbstractNucleic acid therapeutics have shown great potential for the treatment of numerous diseases, such as genetic disorders, cancer and infections. Moreover, they have been successfully used as vaccines during the COVID-19 pandemic. In order to unfold full therapeutical potential, these nano agents have to overcome several barriers. Therefore, directed transport to specific tissues and cell types remains a central challenge to receive carrier systems with enhanced efficiency and desired biodistribution profiles. Active targeting strategies include receptor-targeting, mediating cellular uptake based on ligand-receptor in...
Source: Pharmaceutical Research - September 15, 2022 Category: Drugs & Pharmacology Source Type: research

Dual Blockade of PD-1 and LAG3 Immune Checkpoints Increases Dendritic Cell Vaccine Mediated T Cell Responses in Breast Cancer Model
ConclusionThese findings strongly suggest that TMC-DS-L NPs loaded with siRNA could act as a novel tool in inhibiting the expression of immune checkpoints in the tumor microenvironment. Also, combination therapy based on inhibition of PD-1 and LAG3 in combination with DC vaccine is an effective method in treating cancer that needs to be further studied.
Source: Pharmaceutical Research - June 17, 2022 Category: Drugs & Pharmacology Source Type: research

Combination Cancer Immunotherapy with Dendritic Cell Vaccine and Nanoparticles Loaded with Interleukin-15 and Anti-beta-catenin siRNA Significantly Inhibits Cancer Growth and Induces Anti-Tumor Immune Response
ConclusionsThese findings suggest that the use of new nanocarriers such as SPION-C-CMD-FA could be an effective way to use as a novel combination therapy consisting of β-catenin siRNA, IL-15, and DC vaccine to treat cancer.
Source: Pharmaceutical Research - February 15, 2022 Category: Drugs & Pharmacology Source Type: research

Delivery Strategies for mRNA Vaccines
AbstractThe therapeutic potential for messenger RNA (mRNA) in infectious diseases and cancer was first realized almost three decades ago, but only in 2018 did the first lipid nanoparticle-based small interfering RNA (siRNA) therapy reach the market with the United States Food and Drug Administration (FDA) approval of patisiran (Onpattro ™) for hereditary ATTR amyloidosis. This was largely made possible by major advances in the formulation technology for stabilized lipid-based nanoparticles (LNPs). Design of the cationic ionizable lipids, which are a key component of the LNP formulations, with an acid dissociation constan...
Source: Pharmaceutical Medicine - January 30, 2022 Category: Drugs & Pharmacology Source Type: research

Current advances in self-assembled nanogels for immunotherapy.
Abstract Since nanogels (nanometer-sized gels) were developed two decades ago, they were utilized as carriers of innovative drug delivery systems. In particular, immunological drug delivery via self-assembled nanogels (self-Nanogels) owing to their nanometer size and molecular chaperon-like ability to encapsulate large biomolecules is one of the most well studied and successful applications of nanogels. In the present review, we focus on nanogel applications as immunological drug delivery systems for cancer vaccines, cytokine delivery, nasal vaccines and nucleic acid delivery, including several clinical trials. Ca...
Source: Advanced Drug Delivery Reviews - October 16, 2015 Category: Drugs & Pharmacology Authors: Tahara Y, Akiyoshi K Tags: Adv Drug Deliv Rev Source Type: research

Development of anti-E6 pegylated lipoplexes for mucosal application in the context of cervical preneoplastic lesions
In conclusion, pegylated anti-E6 lipoplexes have demonstrated their efficiency to cross the cellular membrane and to release siRNA into the cytoplasm confirmed by final p53 protein production. Graphical abstract
Source: International Journal of Pharmaceutics - February 27, 2015 Category: Drugs & Pharmacology Source Type: research